As the explants used in the current study represent a sample of quasi-resistant tumours (non-responders) it would be interesting to assess SATB2 and CD80 expression in tissue from LNG responders to determine their clinical applicability as biomarkers of LNG response. This evidence concerns the gene CD80 and neoplasm.